{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/dementia/background-information/causes/","result":{"pageContext":{"chapter":{"id":"f485482d-0d4e-52cb-9df4-3548bc72a566","slug":"causes","fullItemName":"Causes","depth":2,"htmlHeader":"<!-- begin field 4913207b-6890-41df-b6ce-63f5cce00f7d --><h2>What causes it?</h2><!-- end field 4913207b-6890-41df-b6ce-63f5cce00f7d -->","summary":"","htmlStringContent":"<!-- begin item 28a6fda5-7ee3-4b50-8599-68ac585b4179 --><!-- begin field 9b6c8c29-9163-4a8c-8cce-0c5716cac991 --><p><strong>The most common subtypes of dementia are:</strong></p><ul><li><strong>Alzheimer’s disease (50–75% of cases)</strong><ul><li>The pathological features of Alzheimer’s disease (AD) include atrophy of the cerebral cortex and formation of amyloid plaques and neurofibrillary tangles. Acetylcholine production in affected neurones is reduced.</li><li>Post-mortem studies show that AD and vascular dementia often co-exist.</li></ul></li><li><strong>Vascular dementia (up to 20% of cases)</strong><ul><li>Vascular dementia occurs as a result of reduced blood supply to the brain. It can be caused by a wide variety of cerebrovascular disorders, including large or multiple small infarcts, cerebral amyloid angiopathy, and cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL).</li><li>Small vessel disease is common in older people, often alongside AD.</li></ul></li><li><strong>Dementia with Lewy bodies (DLB) — the second most common type of degenerative dementia (10–15% of cases)</strong><ul><li>The main pathological features of DLB are cortical and subcortical Lewy bodies (abnormal deposits of protein inside nerve cells).</li><li>DLB may have similar features to Parkinson's disease dementia. By convention:<ul><li>People who develop cognitive symptoms and motor features of Parkinson's disease within 1 year are classed as having dementia with Lewy bodies.</li><li>People with Parkinson's disease who develop dementia after more than 12 months are classed as having Parkinson's disease dementia.</li></ul></li></ul></li><li><strong>Frontotemporal dementia (FTD) (2% cases)</strong><ul><li>FTD is characterized by progressive degeneration of the frontal and/or temporal lobes. </li><li>FTD tends to have an insidious onset and gradual progression, typically presenting in middle age. Some cases may present very early (the third decade) or very late (ninth decade).</li></ul></li></ul><p><strong>Rarer causes of dementia include:</strong></p><ul><li>Parkinson’s disease (PD) dementia — subcortical dementia occurs in up to 50% of people with PD. Motor symptoms of PD appear many years before dementia. For further information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/parkinsons-disease/\">Parkinson&#39;s disease</a>.</li><li>Progressive supranuclear palsy.</li><li>Huntington’s disease.</li><li>Prion disease (such as Creutzfeldt-Jakob disease [CJD]).</li><li>Normal pressure hydrocephalus.</li><li>Chronic subdural haematoma.</li><li>Benign tumours.</li><li>Metabolic and endocrine disorders (such as chronic hypocalcaemia and recurrent hypoglycaemia).</li><li>Vitamin deficiencies (such as B12 and thiamine deficiency). For further information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/anaemia-b12-folate-deficiency/\">Anaemia - B12 and folate deficiency</a>.</li><li>Infections (such as HIV infection and syphilis). For further information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/hiv-infection-aids/\">HIV infection and AIDS</a>.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/dementia/references/\">Hodges, 2010</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/dementia/references/\">Sorbi, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/dementia/references/\">WHO and Alzheimer&#39;s Disease International, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/dementia/references/\">Alzheimer's Society, 2014a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/dementia/references/\">GPAC, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/dementia/references/\">Mayo, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/dementia/references/\">NICE, 2015a</a>]</p><!-- end field 9b6c8c29-9163-4a8c-8cce-0c5716cac991 --><!-- end item 28a6fda5-7ee3-4b50-8599-68ac585b4179 -->","topic":{"id":"de9cbb4d-2d69-500f-be27-dc83f76dc3ba","topicId":"2491e3e7-cc21-42b9-8972-e54804b4782f","topicName":"Dementia","slug":"dementia","lastRevised":"Last revised in October 2020","chapters":[{"id":"af834011-0042-530a-8f9a-acd5828e0a34","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"a0360b83-4555-5079-897f-12b2d555c1af","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"52cd8e36-39cd-5259-8819-bd96087b0265","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"60bd6b27-027f-56a6-a018-a1d694a6a2f3","slug":"changes","fullItemName":"Changes"},{"id":"7ced1224-30c2-5f30-9caf-3764f3665ae4","slug":"update","fullItemName":"Update"}]},{"id":"fae05cff-ad98-52fa-89b4-b97369195d59","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"2f3b4bd3-e7cf-5492-afe0-0a5b230eab7e","slug":"goals","fullItemName":"Goals"},{"id":"9104785e-e491-5ca3-b3d3-7e951385bce9","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"a9c56eb4-bc0e-51cc-b486-a54c23906bc0","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"ebf62eba-a4cd-536c-8c9f-c9505b0e7482","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"a71b8dc2-79f8-5d24-b668-c792abc5a624","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"c87232ba-6926-5ff2-98d2-f8839b0c0d37","slug":"nice-quality-standards","fullItemName":"NICE Quality Standards"}]},{"id":"825c29c3-9d55-54ae-b54d-8ee2ac796e97","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"46c6316f-eec0-580a-80ec-2112d2f0122f","slug":"definition","fullItemName":"Definition"},{"id":"f485482d-0d4e-52cb-9df4-3548bc72a566","slug":"causes","fullItemName":"Causes"},{"id":"87101d89-6073-57cc-b247-48be586ef185","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"58f6ec5a-c90b-5e64-a476-fc9fca39c6ae","slug":"prevalence","fullItemName":"Prevalence"},{"id":"994469e3-f824-5f48-b755-7f74dd360680","slug":"prognosis","fullItemName":"Prognosis"},{"id":"718f9ed4-d725-5f6e-a86f-5df88719cd52","slug":"complications","fullItemName":"Complications"}]},{"id":"366bcbe3-827a-5e08-9d81-8de84e46fefd","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"565bac2a-ada3-5b0a-ab7d-6681501b2c4a","slug":"clinical-features","fullItemName":"Clinical features"},{"id":"4c0fe55f-40c9-5a1c-8cf3-1ec8d88406d5","slug":"assessment","fullItemName":"Assessment"},{"id":"ef7780bd-8e94-5f95-870f-92ab930c4365","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"3069f5e5-519f-50ec-81b7-c8948a5b3117","fullItemName":"Management","slug":"management","subChapters":[{"id":"c6c0cbc2-18fc-5bf8-973d-bc38b9001f28","slug":"suspected-dementia","fullItemName":"Scenario: Suspected dementia"},{"id":"6320a2da-e9d6-5f57-94d9-0433261edf89","slug":"follow-up-of-confirmed-dementia-in-primary-care","fullItemName":"Scenario: Follow up of confirmed dementia in primary care"},{"id":"343a59fa-439e-5ab9-9d3b-28a893d55d2f","slug":"management-of-end-stage-dementia","fullItemName":"Scenario: Management of end-stage dementia"}]},{"id":"9a2639de-07aa-5fe3-8f09-5c005f9c29dd","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"58ed8441-e3ca-566e-9afb-92a5ba60b1dd","slug":"haloperidol","fullItemName":"Haloperidol"},{"id":"67092bd7-2ab4-5e8b-8ead-5301454da4a8","slug":"acetylcholinesterase-inhibitors","fullItemName":"Acetylcholinesterase inhibitors"},{"id":"f4ced652-a6de-5e19-ae37-6de43dfd8104","slug":"lorazepam","fullItemName":"Lorazepam"},{"id":"45d5f01b-c1c2-53dc-91b4-8f7a90983fd5","slug":"memantine-hydrochloride","fullItemName":"Memantine hydrochloride"}]},{"id":"1e87c908-2ab5-5cba-8d6a-958c03f7a6cd","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"fc7a2bcf-854b-5ca4-9b02-2dcaaebe1162","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"7bcb26a3-cc69-5201-9fd9-6353e27b412f","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"0c383917-58d0-5036-8217-5d9fd81cb2cb","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"fdb8af52-aeee-52bd-be79-c5534939d42f","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"a9f930f3-f8b6-5c8f-b8ca-b3155e0c23d3","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"668c11fa-1873-58d4-b0e2-3eab90e8fbff","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"67c4aef9-fbf4-5bf6-8dc5-c501f74b1fe3","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"825c29c3-9d55-54ae-b54d-8ee2ac796e97","slug":"background-information","fullItemName":"Background information"},"subChapters":[]}}},"staticQueryHashes":["3666801979"]}